Obiageli Ogbata, MD
Medical Oncology · Charlotte, NCNPI 1346552692
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.5%. Reporting peaked in 2024 at $13,009 and has fallen 76.7% since, to $3,036 in 2025.
Across 111 payments — averaging $230.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$4K
- E.r. Squibb & Sons, L.L.C.$4K
- Exelixis Inc.$3K
- Genentech USA, Inc.$3K
- AbbVie$2K
- Coherus Oncology, Inc.$2K
- plus $6K from 30 others
Across 22 payments — averaging $37,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$678K
- AstraZeneca$64K
- Takeda Pharmaceuticals U.S.A., Inc.$44K
- Astrazeneca UK Limited$37K
- Iovance Biotherapeutics, Inc.$13K
What the payments were for
- Consulting fees$15,29060%
- Speaking & faculty fees$4,00216%
- Travel & lodging$2,0118%
- Food & beverage$4,16016%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $4,460 |
| E.r. Squibb & Sons, L.L.C. | 12 | $4,368 |
| Exelixis Inc. | 10 | $3,196 |
| Genentech USA, Inc. | 6 | $2,750 |
| AbbVie | 2 | $2,419 |
| Coherus Oncology, Inc. | 3 | $2,317 |
| AstraZeneca | 8 | $2,180 |
| Bayer | 3 | $955 |
| EMD Serono, Inc. | 5 | $470 |
| Gilead(2 entities) | 11 | $443 |
| Johnson & Johnson(2 entities) | 11 | $273 |
| Amgen(2 entities) | 2 | $242 |
| Viiv Healthcare Company | 2 | $211 |
| Vertex | 1 | $140 |
| Novocure Inc. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Advanced Accelerator Applications | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $114 |
| Davol Inc. | 1 | $92 |
| Novartis | 3 | $79 |
| Incyte Corporation | 3 | $61 |
| Sanofi | 1 | $55 |
| Array Biopharma Inc | 2 | $40 |
| Beone Medicines USA, Inc. | 2 | $36 |
| Tempus AI, Inc | 1 | $29 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Iovance Biotherapeutics, Inc. | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Merck | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,551 in reported general payments places this provider in the 80th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 18 | $292,074 |
| MekinistTrametinib Dimethyl Sulfoxide | 17 | $255,730 |
| TafinlarDabrafenib Mesylate | 17 | $235,539 |
| EliquisApixaban | 51 | $40,849 |
| Cevimeline Hcl | 11 | $2,290 |
| Megestrol Acetate | 12 | $1,232 |
| Levothyroxine Sodium | 89 | $757 |
| Gabapentin | 31 | $525 |
| Clobetasol Propionate | 17 | $506 |
| Potassium Chloride | 56 | $397 |
| Hydralazine Hcl | 21 | $390 |
| Duloxetine Hcl | 33 | $374 |
| Hydroxyurea | 18 | $330 |
| Anastrozole | 14 | $312 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMekinist, Tafinlar | $79 | $491,26934 claims |
| AstraZenecaTagrisso | $2,180 | $292,07418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Edward KimCharlotte$188K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.